USO 20398
A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors (Wo42178/Engot-Gyn2/Gog-3051)
Disease Types: GYN Cancer Research
Eligibility Requirements:
-persistent or recurrent epithelial ovarian carcinoma not amenable to curative surgery
-measurable disease, previous treatment with 1-4 lines of therapy with at least one that was platinum based
-No: hepatitis B, hepatitis C; pleural or pericardial effusions or ascites requiring recurrent drainage; uncontrolled and/or symptomatic hypercalcemia; symptomatic, untreated, or progressive central nervous system metastasis; history of leptomeningeal disease.
Available at: